Protective effects of lactoferrin chimera and bovine lactoferrin in a mouse model of enterohaemorrhagic Escherichia coli O157:H7 infection

Biochemistry and Cell Biology

Volumn 90, Issue 3, 2012, Pages 405-411

  Flores Villaseñor, H́ctor ^a   Canizalez Román, Adrian ^a   Velazquez Roman, Jorge ^b   Nazmi, Kamran ^c   Bolscher, Jan G M ^c   Leon Sicairos, Nidia ^a,d  

^a UNIVERSIDAD AUTÓNOMA DE SINALOA   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Servicio de Hematología Y Oncología Hospital Pediátrico de Sinaloa Dr Rigoberto Aguilar Pico   (Mexico)

Author keywords

Chimera; EHEC; Lactoferrin; Mortality; Mouse

Indexed keywords

CHIMERA; EHEC; LACTOFERRIN; MORTALITY; MOUSE;

ESCHERICHIA COLI; POPULATION STATISTICS;

MAMMALS;

BOVINE LACTOFERRIN; KANAMYCIN; LACTOFERRIN; LF CHIMERA; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CHIMERA; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SYNTHESIS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; FECES ANALYSIS; GLOMERULOPATHY; INTESTINE INFECTION; KIDNEY INJURY; KIDNEY PARENCHYMA; KIDNEY TUBULE NECROSIS; LIVER; LIVER INJURY; MALE; MORTALITY; MOUSE; NONHUMAN; SEPSIS; URINARY CAST;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTEREMIA; CATTLE; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FECES; INTESTINES; KANAMYCIN; KIDNEY; LACTOFERRIN; LIVER; MALE; MICE; MICE, INBRED BALB C;

BACTERIA (MICROORGANISMS); BOVINAE; ESCHERICHIA COLI; MUS;

EID: 84861362841     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/o11-089     Document Type: Article

References (37)

1. Abu-Ali G.S. Ouellette L.M. Henderson S.T. Whittam T.S. Manning S.D. 2010. Differences in adherence and virulence gene expression between two outbreak strains of enterohaemorrhagic Escherichia coli O157: H7. Microbiology, 156 (2): 408-419. 10.1099/mic.0.033126-0 19892762
2. Alpers K. Werber D. Frank C. Koch J. Friedrich A.W. Karch H. et al. 2009. Sorbitol-fermenting enterohaemorrhagic Escherichia coli O157:H-causes another outbreak of haemolytic uraemic syndrome in children. Epidemiol. Infect. 137 (3): 389-395. 10.1017/S0950268808001465 19021923
3. Arnold R.R. Cole M.F. McGhee J.R. 1977. A bactericidal effect for human lactoferrin. Science, 197 (4300): 263-265. 10.1126/science.327545 327545
4. Bellamy W. Takase M. Wakabayashi H. Kawase K. Tomita M. 1992. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73 (6): 472-479. 10.1111/j.1365-2672.1992.tb05007.x 1490908
5. Bielaszewska M. Mellmann A. Zhang W. Kock R. Fruth A. Bauwens A. et al. 2011. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect. Dis. 11 (9): 671-676. 21703928
6. Bolscher J.G. Adao R. Nazmi K. van den Keybus P.A. van 't Hof W. Nieuw Amerongen A.V. et al. 2009. Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie, 91 (1): 123-132. 10.1016/j.biochi.2008.05. 019 18573310
7. Chaisri U. Nagata M. Kurazono H. Horie H. Tongtawe P. Hayashi H. et al. 2001. Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome. Microb. Pathog. 31 (2): 59-67. 10.1006/mpat.2001.0447 11453701
8. Chodaczek G. Zimecki M. Lukasiewicz J. Lugowski C. 2008. Lactoferrin-monophosphoryl lipid A complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92. Acta Biochim. Pol. 55 (1): 91-96. 18231655
9. Faix R.G. 2010. Bovine lactoferrin appears to decrease the incidence of sepsis in very low-birth weight infants. J. Pediatr. 156 (5): 856. 10.1016/j.jpeds.2010.02.052 20385324
10. Farnaud S. Evans R.W. 2003. Lactoferrin a multifunctional protein with antimicrobial properties. Mol. Immunol. 40 (7): 395-405. 10.1016/S0161-5890(03) 00152-4 14568385
11. Flores-Villaseñor H. Canizalez-Román A. Reyes-Lopez M. Nazmi K. de la Garza M. Zazueta-Beltrán J. et al. 2010. Bactericidal effect of bovine lactoferrin, LFcin, LFampin and LFchimera on antibiotic-resistant Staphylococcus aureus and Escherichia coli. Biometals, 23 (3): 569-578. 10.1007/s10534-010-9306-4 20195887
12. Frank C. Werber D. Cramer J.P. Askar M. Faber M. an der Heiden M. et al. 2011. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365 (19): 1771-1780. 10.1056/NEJMoa1106483 21696328
13. Germani Y. Cunin P. Tedjouka E. Ncharre C.B. Morvan J. Martin P. 1998. Enterohaemorrhagic Escherichia coli in Ngoila (Cameroon) during an outbreak of bloody diarrhoea. Lancet, 352 (9128): 625-626. 10.1016/S0140-6736(05)79581-7 9746033
14. Girard F. Frankel G. Phillips A.D. Cooley W. Weyer U. Dugdale A.H. et al. 2008. Interaction of enterohemorrhagic Escherichia coli O157:H7 with mouse intestinal mucosa. FEMS Microbiol. Lett. 283 (2): 196-202. 10.1111/j.1574-6968. 2008.01166.x 18422621
15. Haney E.F. Lau F. Vogel H.J. 2007. Solution structures and model membrane interactions of lactoferrampin, an antimicrobial peptide derived from bovine lactoferrin. Biochim. Biophys. Acta, 1768 (10): 2355-2364.
16. Kaper J.B. Nataro J.P. Mobley H.L. 2004. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2 (2): 123-140. 10.1038/nrmicro818 15040260
17. Leon-Sicairos N. Canizalez-Roman A. de la Garza M. Reyes-Lopez M. Zazueta-Beltran J. Nazmi K. et al. 2009. Bactericidal effect of lactoferrin and lactoferrin chimera against halophilic Vibrio parahaemolyticus. Biochimie, 91 (1): 133-140. 10.1016/j.biochi.2008.06.009 18625283
18. Lindgren S.W. Melton A.R. O'Brien A.D. 1993. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect. Immun. 61 (9): 3832-3842. 8359904
19. Manzoni P. Rinaldi M. Cattani S. Pugni L. Romeo M.G. Messner H. et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. 2009. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA, 302 (13): 1421-1428. 10.1001/jama.2009.1403 19809023
20. Manzoni P. Decembrino L. Stolfi I. Pugni L. Rinaldi M. Cattani S. et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections Italian Society of Neonatology. 2010. Lactoferrin and prevention of late-onset sepsis in the pre-term neonates. Early Hum. Dev. 86 (Suppl. 1): 59-61. 10.1016/j.earlhumdev.2010.01.009 20138718
21. Mark Taylor C. 2008. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr. Nephrol. 23 (9): 1425-1431. 10.1007/s00467-008-0820-3 18493800
22. Mohawk K.L. O'Brien A.D. 2011. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J. Biomed. Biotechnol. 2011: 258185. 10.1155/2011/258185 21274267
23. Much P. Pichler J. Allerberger F. 2007. [Food borne infectious outbreaks, Austria 2005]. Wien. Klin. Wochenschr. 119 (5-6): 150-157. 10.1007/s00508-006- 0746-3 17427017
24. Nataro J.P. Kaper J.B. 1998. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11 (1): 142-201. 9457432
25. Orsi N. 2004. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals, 17 (3): 189-196. 10.1023/B:BIOM.0000027691.86757.e2 15222464
26. Pierce A. Legrand D. Mazurier J. 2009. [Lactoferrin: a multifunctional protein]. Med. Sci. (Paris), 25 (4): 361-369. 10.1051/medsci/2009254361 19409188
27. Sartz L. De Jong B. Hjertqvist M. Plym-Forshell L. Alsterlund R. Lofdahl S. et al. 2008. An outbreak of Escherichia coli O157:H7 infection in southern Sweden associated with consumption of fermented sausage; aspects of sausage production that increase the risk of contamination. Epidemiol. Infect. 136 (3): 370-380. 10.1017/S0950268807008473 17445322
28. Sawamura S. Tanaka K. Koga Y. 1999. [Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice]. Kansenshogaku Zasshi, 73 (10): 1054-1063. 10565122
29. Shin K. Yamauchi K. Teraguchi S. Hayasawa H. Tomita M. Otsuka Y. Yamazaki S. 1998. Antibacterial activity of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157:H7. Lett. Appl. Microbiol. 26 (6): 407-411. 10.1046/j.1472-765X.1998.00358.x 9717310
30. Söderström A. Lindberg A. Andersson Y. 2005. EHEC O157 outbreak in Sweden from locally produced lettuce, August-September 2005. Euro Surveill. 10 (9): E050922.1. 16788234
31. van der Kraan M.I. Groenink J. Nazmi K. Veerman E.C. Bolscher J.G. Nieuw Amerongen A.V. 2004. Lactoferrampin: a novel antimicrobial peptide in the N1-domain of bovine lactoferrin. Peptides, 25 (2): 177-183. 10.1016/j.peptides. 2003.12.006 15062998
32. Venkatesh M.P. Abrams S.A. 2010. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst. Rev. (5): CD007137. 20464748
33. Welinder-Olsson C. Stenqvist K. Badenfors M. Brandberg A. Floŕn K. Holm M. et al. 2004. EHEC outbreak among staff at a children's hospital use of PCR for verocytotoxin detection and PFGE for epidemiological investigation. Epidemiol. Infect. 132 (1): 43-49. 10.1017/S0950268803001444 14979588
34. Wong C.S. Jelacic S. Habeeb R.L. Watkins S.L. Tarr P.I. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342 (26): 1930-1936. 10.1056/ NEJM200006293422601 10874060
35. Yoshimura K. Fujii J. Taniguchi H. Yoshida S. 1999. Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol. Med. Microbiol. 26 (2): 101-108. 10.1111/j.1574-695X.1999.tb01376.x 10536295
36. Zagulski T. Lipinski P. Zagulska A. Broniek S. Jarzabek Z. 1989. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br. J. Exp. Pathol. 70 (6): 697-704. 2690922
37. Zimecki M. Artym J. Chodaczek G. Kocieba M. Kruzel M.L. 2004. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm. Res. 53 (7): 292-296. 10.1007/s00011-004-1257-1 15241563